431 related articles for article (PubMed ID: 11472109)
1. High and sustained transgene expression in vivo from plasmid vectors containing a hybrid ubiquitin promoter.
Yew NS; Przybylska M; Ziegler RJ; Liu D; Cheng SH
Mol Ther; 2001 Jul; 4(1):75-82. PubMed ID: 11472109
[TBL] [Abstract][Full Text] [Related]
2. Sustained liver-specific transgene expression from the albumin promoter in mice following hydrodynamic plasmid DNA delivery.
Wooddell CI; Reppen T; Wolff JA; Herweijer H
J Gene Med; 2008 May; 10(5):551-63. PubMed ID: 18330848
[TBL] [Abstract][Full Text] [Related]
3. Sustained, high transgene expression in liver with plasmid vectors using optimized promoter-enhancer combinations.
Magnusson T; Haase R; Schleef M; Wagner E; Ogris M
J Gene Med; 2011 Jul; 13(7-8):382-91. PubMed ID: 21721074
[TBL] [Abstract][Full Text] [Related]
4. Increased duration of transgene expression in the lung with plasmid DNA vectors harboring adenovirus E4 open reading frame 3.
Yew NS; Marshall J; Przybylska M; Wysokenski DM; Ziegler RJ; Rafter PW; Li C; Armentano D; Cheng SH
Hum Gene Ther; 1999 Jul; 10(11):1833-43. PubMed ID: 10446923
[TBL] [Abstract][Full Text] [Related]
5. Increased persistence of lung gene expression using plasmids containing the ubiquitin C or elongation factor 1alpha promoter.
Gill DR; Smyth SE; Goddard CA; Pringle IA; Higgins CF; Colledge WH; Hyde SC
Gene Ther; 2001 Oct; 8(20):1539-46. PubMed ID: 11704814
[TBL] [Abstract][Full Text] [Related]
6. CMV enhancer/human PDGF-beta promoter for neuron-specific transgene expression.
Liu BH; Wang X; Ma YX; Wang S
Gene Ther; 2004 Jan; 11(1):52-60. PubMed ID: 14681697
[TBL] [Abstract][Full Text] [Related]
7. Improved neuronal transgene expression from an AAV-2 vector with a hybrid CMV enhancer/PDGF-beta promoter.
Wang CY; Guo HY; Lim TM; Ng YK; Neo HP; Hwang PY; Yee WC; Wang S
J Gene Med; 2005 Jul; 7(7):945-55. PubMed ID: 15756650
[TBL] [Abstract][Full Text] [Related]
8. Reduced inflammatory response to plasmid DNA vectors by elimination and inhibition of immunostimulatory CpG motifs.
Yew NS; Zhao H; Wu IH; Song A; Tousignant JD; Przybylska M; Cheng SH
Mol Ther; 2000 Mar; 1(3):255-62. PubMed ID: 10933941
[TBL] [Abstract][Full Text] [Related]
9. In vivo electroporation and ubiquitin promoter--a protocol for sustained gene expression in the lung.
Gazdhar A; Bilici M; Pierog J; Ayuni EL; Gugger M; Wetterwald A; Cecchini M; Schmid RA
J Gene Med; 2006 Jul; 8(7):910-8. PubMed ID: 16685743
[TBL] [Abstract][Full Text] [Related]
10. Partial correction of the alpha-galactosidase A deficiency and reduction of glycolipid storage in Fabry mice using synthetic vectors.
Przybylska M; Wu IH; Zhao H; Ziegler RJ; Tousignant JD; Desnick RJ; Scheule RK; Cheng SH; Yew NS
J Gene Med; 2004 Jan; 6(1):85-92. PubMed ID: 14716680
[TBL] [Abstract][Full Text] [Related]
11. Promoters influence the kinetics of transgene expression following adenovector gene delivery.
Chen P; Tian J; Kovesdi I; Bruder JT
J Gene Med; 2008 Feb; 10(2):123-31. PubMed ID: 18064718
[TBL] [Abstract][Full Text] [Related]
12. Long-term transgene expression from plasmid DNA gene therapy vectors is negatively affected by CpG dinucleotides.
Hodges BL; Taylor KM; Joseph MF; Bourgeois SA; Scheule RK
Mol Ther; 2004 Aug; 10(2):269-78. PubMed ID: 15294174
[TBL] [Abstract][Full Text] [Related]
13. Sustained expression after nonviral ocular gene transfer using mammalian promoters.
Kachi S; Esumi N; Zack DJ; Campochiaro PA
Gene Ther; 2006 May; 13(9):798-804. PubMed ID: 16467860
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of Tet-on system to avoid transgene down-regulation in ex vivo gene transfer to the CNS.
Johansen J; Rosenblad C; Andsberg K; Møller A; Lundberg C; Björlund A; Johansen TE
Gene Ther; 2002 Oct; 9(19):1291-301. PubMed ID: 12224012
[TBL] [Abstract][Full Text] [Related]
15. Time course of gene expression after plasmid DNA gene transfer to the liver.
Herweijer H; Zhang G; Subbotin VM; Budker V; Williams P; Wolff JA
J Gene Med; 2001; 3(3):280-91. PubMed ID: 11437333
[TBL] [Abstract][Full Text] [Related]
16. Hepatocyte-specific gene expression from integrated lentiviral vectors.
Nash KL; Jamil B; Maguire AJ; Alexander GJ; Lever AM
J Gene Med; 2004 Sep; 6(9):974-83. PubMed ID: 15352070
[TBL] [Abstract][Full Text] [Related]
17. Activator protein 1-mediated transcriptional regulation strategy sustains long-term expression of a xenogeneic gene product in vivo: an implication for gene therapy targeting congenital protein deficiencies.
Sasaki S; Smith JM; Takase K; Okuda K; Ishii N; Takeshita F
Int J Mol Med; 2006 Aug; 18(2):289-97. PubMed ID: 16820937
[TBL] [Abstract][Full Text] [Related]
18. Optimization of plasmid vectors for high-level expression in lung epithelial cells.
Yew NS; Wysokenski DM; Wang KX; Ziegler RJ; Marshall J; McNeilly D; Cherry M; Osburn W; Cheng SH
Hum Gene Ther; 1997 Mar; 8(5):575-84. PubMed ID: 9095409
[TBL] [Abstract][Full Text] [Related]
19. Transient siRNA-mediated attenuation of liver expression from an alpha-galactosidase A plasmid reduces subsequent humoral immune responses to the transgene product in mice.
Chu Q; Joseph M; Przybylska M; Yew NS; Scheule RK
Mol Ther; 2005 Aug; 12(2):264-73. PubMed ID: 15946902
[TBL] [Abstract][Full Text] [Related]
20. Muscle creatine kinase/SV40 hybrid promoter for muscle-targeted long-term transgene expression.
Takeshita F; Takase K; Tozuka M; Saha S; Okuda K; Ishii N; Sasaki S
Int J Mol Med; 2007 Feb; 19(2):309-15. PubMed ID: 17203206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
